Correction: Halofuginone inhibits radiotherapy-induced epithelial-mesenchymal transition in lung cancer [Oncotarget., 7, (2016), (71341-71352)] DOI: 10.18632/oncotarget.11217;Halofuginone inhibits radiotherapy-induced epithelialmesenchymal transition in lung cancer

Oncotarget

Volumn 7, Issue 44, 2016, Pages 71341-71352

  Chen, Yang ^a   Liu, Weishuai ^b   Wang, Peng ^c   Hou, Hailing ^a   Liu, Ningbo ^a   Gong, Linlin ^a   Wang, Youyou ^a   Ji, Kai ^b   Zhao, Lujun ^a   Wang, Ping ^a  

^a KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY INTERNATIONAL HOSPITAL   (China)

Author keywords

Epithelial mesenchymal transition (EMT); Halofuginone; Lung cancer; Radiotherapy; Transforming growth factor (TGF 1)

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; CYTOKERATIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HALOFUGINONE; NERVE CELL ADHESION MOLECULE; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VIMENTIN; 1,3 DIOXOLANE DERIVATIVE; 4-(5-BENZO(1,3)DIOXOL-5-YL-4-PYRIDIN-2-YL-1H-IMIDAZOL-2-YL)BENZAMIDE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; MORPHOLOGY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL MOTION; DRUG EFFECTS; DRUG SCREENING; LUNG TUMOR; PATHOLOGY; PHYSIOLOGY; RADIATION RESPONSE; TUMOR INVASION;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CARCINOMA, LEWIS LUNG; CELL MOVEMENT; DIOXOLES; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; PIPERIDINES; QUINAZOLINONES; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84995395652     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.25958     Document Type: Erratum

References (32)

1. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell. 2009; 139:871-890
2. Kawamoto A, Yokoe T, Tanaka K, Saigusa S, Toiyama Y, Yasuda H, Inoue Y, Miki C, Kusunoki M. Radiation induces epithelial-mesenchymal transition in colorectal cancer cells. Oncol Rep. 2012; 27:51-57
3. Rube CE, Uthe D, Schmid KW, Richter KD, Wessel J, Schuck A, Willich N, Rube C. Dose-dependent induction of transforming growth factor beta (TGF-beta) in the lung tissue of fibrosis-prone mice after thoracic irradiation. Int J Radiat Oncol Biol Phys. 2000; 47:1033-1042
4. Ganapathy V, Ge R, Grazioli A, Xie W, Banach-Petrosky W, Kang Y, Lonning S, McPherson J, Yingling JM, Biswas S, Mundy GR, Reiss M. Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer. 2010; 9:122
5. Perez RE, Navarro A, Rezaiekhaligh MH, Mabry SM, Ekekezie, II. TRIP-1 regulates TGF-beta1-induced epithelial-mesenchymal transition of human lung epithelial cell line A549. Am J Physiol Lung Cell Mol Physiol. 2011; 300:L799-807
6. Sheffer Y, Leon O, Pinthus JH, Nagler A, Mor Y, Genin O, Iluz M, Kawada N, Yoshizato K, Pines M. Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect. Mol Cancer Ther. 2007; 6:570-577
7. Xavier S, Piek E, Fujii M, Javelaud D, Mauviel A, Flanders KC, Samuni AM, Felici A, Reiss M, Yarkoni S, Sowers A, Mitchell JB, Roberts AB, et al. Amelioration of radiationinduced fibrosis: inhibition of transforming growth factorbeta signaling by halofuginone. J Biol Chem. 2004; 279:15167-15176
8. Juarez P, Mohammad KS, Yin JJ, Fournier PG, McKenna RC, Davis HW, Peng XH, Niewolna M, Javelaud D, Chirgwin JM, Mauviel A, Guise TA. Halofuginone inhibits the establishment and progression of melanoma bone metastases. Cancer Res. 2012; 72:6247-6256
9. Lin R, Yi S, Gong L, Liu W, Wang P, Liu N, Zhao L, Wang P. Inhibition of TGF-beta signaling with halofuginone can enhance the antitumor effect of irradiation in Lewis lung cancer. Onco Targets Ther. 2015; 8:3549-3559
10. Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C, Fauvet F, Puisieux I, Doglioni C, Piccinin S, Maestro R, Voeltzel T, Selmi A, et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell. 2008; 14:79-89
11. Zheng H, Li W, Wang Y, Liu Z, Cai Y, Xie T, Shi M, Wang Z, Jiang B. Glycogen synthase kinase-3 beta regulates Snail and beta-catenin expression during Fas-induced epithelialmesenchymal transition in gastrointestinal cancer. Eur J Cancer. 2013; 49:2734-2746
12. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997; 390:465-471
13. Massague J, Wotton D. Transcriptional control by the TGFbeta/Smad signaling system. Embo j. 2000; 19:1745-1754
14. Shi Y, Hata A, Lo RS, Massague J, Pavletich NP. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature. 1997; 388:87-93
15. Lebrun JJ, Takabe K, Chen Y, Vale W. Roles of pathwayspecific and inhibitory Smads in activin receptor signaling. Mol Endocrinol. 1999; 13:15-23
16. Ishisaki A, Yamato K, Hashimoto S, Nakao A, Tamaki K, Nonaka K, ten Dijke P, Sugino H, Nishihara T. Differential inhibition of Smad6 and Smad7 on bone morphogenetic protein-and activin-mediated growth arrest and apoptosis in B cells. J Biol Chem. 1999; 274:13637-13642
17. Luo L, Li N, Lv N, Huang D. SMAD7: a timer of tumor progression targeting TGF-beta signaling. Tumour Biol. 2014; 35:8379-8385
18. Micalizzi DS, Farabaugh SM, Ford HL. Epithelialmesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010; 15:117-134
19. Tsukamoto H, Shibata K, Kajiyama H, Terauchi M, Nawa A, Kikkawa F. Irradiation-induced epithelialmesenchymal transition (EMT) related to invasive potential in endometrial carcinoma cells. Gynecol Oncol. 2007; 107:500-504
20. Zoni E, van der Pluijm G, Gray PC, Kruithof-de Julio M. Epithelial Plasticity in Cancer: Unmasking a MicroRNA Network for TGF-beta-, Notch-, and Wnt-Mediated EMT. J Oncol. 2015; 2015:198967
21. Dancea HC, Shareef MM, Ahmed MM. Role of Radiationinduced TGF-beta Signaling in Cancer Therapy. Mol Cell Pharmacol. 2009; 1:44-56
22. Mantel PY, Schmidt-Weber CB. Transforming growth factor-beta: recent advances on its role in immune tolerance. Methods Mol Biol. 2011; 677:303-338
23. Tsuchida K, Nakatani M, Hitachi K, Uezumi A, Sunada Y, Ageta H, Inokuchi K. Activin signaling as an emerging target for therapeutic interventions. Cell Commun Signal. 2009; 7:15
24. Kim ES, Kim MS, Moon A. Transforming growth factor (TGF)-beta in conjunction with H-ras activation promotes malignant progression of MCF10A breast epithelial cells. Cytokine. 2005; 29:84-91
25. Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H, Kraut N, Beug H, Wirth T. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest. 2004; 114:569-581
26. Xue G, Restuccia DF, Lan Q, Hynx D, Dirnhofer S, Hess D, Ruegg C, Hemmings BA. Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-beta signaling axes. Cancer Discov. 2012; 2:248-259
27. Lamouille S, Derynck R. Cell size and invasion in TGFbeta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol. 2007; 178:437-451
28. Lamouille S, Connolly E, Smyth JW, Akhurst RJ, Derynck R. TGF-beta-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci. 2012; 125:1259-1273
29. Tania M, Khan MA, Fu J. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol. 2014; 35:7335-7342
30. Zhang X, Li Y, Zhang Y, Song J, Wang Q, Zheng L, Liu D. Beta-elemene blocks epithelial-mesenchymal transition in human breast cancer cell line MCF-7 through Smad3-mediated down-regulation of nuclear transcription factors. PLoS One. 2013; 8:e58719
31. Jin ML, Park SY, Kim YH, Park G, Lee SJ. Halofuginone induces the apoptosis of breast cancer cells and inhibits migration via downregulation of matrix metalloproteinase-9. Int J Oncol. 2014; 44:309-318
32. Pines M. Targeting TGFbeta signaling to inhibit fibroblast activation as a therapy for fibrosis and cancer: effect of halofuginone. Expert Opin Drug Discov. 2008; 3:11-20